Periodic Reporting for period 1 - CMI2T IA (Harmless Clostridium bacteria as a highly targeted, continuous delivery system for immunomodulatory anti-cancer drugs)

The goal of the project, CMI2T IA, is to determine the feasibility and lead the development of a new line of R&D in DualTPharma BV (DTP). This comprises the application of non-pathogenic Clostridium bacteria as a novel tumour delivery vehicle for anti-cancer drugs. This will...